Gilead Sciences awaits a booster

Shareholders of Biopharmaceutical firm, Gilead Sciences (GILD,) might be starting to wonder if it’s time to cash out.

Gilead logo
Source: Bloomberg

The stock has run up 40% since the start of the year, particularly with the US approval of selling its hepatitis C drug, Harvoni.

However, GILD has started to lose some steam over the past month. After hitting an all-time high  of $114.22 just over a month ago, its stock price has since dropped about 8%.

Some of this pressure has come from the growing concerns   that competitive rival drug maker AbbVie could significantly undercut Gilead Sciences in order to win the market share.

We could also see some headwinds with reports last night that Gilead is the target of legal action. Southeastern Pennsylvania Transportation Authority (SEPTA), has filed a lawsuit against the company, accusing it of ‘exorbitant pricing’ over another of its hepatitis C drug, Sovaldi.

Investor’s sentiment could take a further dent on the back of these events, which could see a further pullback in GILD’s stock price.

From a technical perspective, on the daily chart GILD appears to be trading within an upward channel. In the short term its being supported by a floor of $100 and capped by a ceiling of $110.

Fundamentally, there has yet to be any significant material changes in the company, which will be a source of optimism for long-term investors.  The market is generally optimistic on its pipeline of products, which includes clinical trials of at least six potential blockbuster products, such as non-alcoholic steatohepatitis and catering to a range of blood-based disorders.

A pullback towards the support level will present an attractive entry to go long. The stock currently has a 12-month market consensus target price of $126.26 – an upside of over 20%, according to a Bloomberg analyst poll. There are 27 buy calls, 5 hold calls, and none recommending a sell call, based on the survey.

Click to enlarge

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Find articles by analysts

Een artikel zoeken

Form has failed to submit. Please contact IG directly.

  • Ik wens per e-mail informatie van IG Group bedrijven te ontvangen over handelsideeën en IG's producten en diensten.

Voor meer informatie over hoe wij uw gegevens mogelijk kunnen gebruiken, bekijkt u ons Privacy- en toegangsbeleid en onze privacy website.

CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen. 79% van de retailbeleggers lijdt verlies op de handel in CFD’s met deze aanbieder.
Het is belangrijk dat u goed begrijpt hoe CFD's werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen.